FY2022 EPS Estimates for Nyxoah S.A. (NASDAQ:NYXH) Increased by Cantor Fitzgerald

Nyxoah S.A. (NASDAQ:NYXHGet Rating) – Equities research analysts at Cantor Fitzgerald upped their FY2022 earnings estimates for shares of Nyxoah in a research note issued on Wednesday, May 11th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($1.47) per share for the year, up from their prior estimate of ($1.71).

NYXH has been the subject of several other reports. Zacks Investment Research downgraded Nyxoah from a “buy” rating to a “hold” rating in a report on Friday, April 1st. Piper Sandler lowered their price target on Nyxoah from $40.00 to $30.00 in a report on Friday, March 25th. Oppenheimer initiated coverage on Nyxoah in a report on Wednesday, April 20th. They issued an “outperform” rating and a $30.00 price target for the company. Finally, Wolfe Research started coverage on Nyxoah in a report on Tuesday, April 5th. They issued a “market perform” rating and a $21.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $31.33.

Shares of Nyxoah stock opened at $14.13 on Friday. Nyxoah has a 1 year low of $14.02 and a 1 year high of $37.00. The business has a 50-day moving average of $18.05 and a two-hundred day moving average of $20.18. The company has a debt-to-equity ratio of 0.07, a quick ratio of 12.07 and a current ratio of 10.41.

Hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Nyxoah in the third quarter valued at approximately $19,612,000. Evolutionary Tree Capital Management LLC acquired a new stake in shares of Nyxoah in the third quarter valued at approximately $1,126,000. Credit Suisse AG acquired a new stake in shares of Nyxoah in the third quarter valued at approximately $221,000. AXA S.A. acquired a new stake in Nyxoah during the 3rd quarter worth approximately $5,118,000. Finally, Putnam Investments LLC acquired a new stake in Nyxoah during the 3rd quarter worth approximately $5,646,000. Hedge funds and other institutional investors own 10.76% of the company’s stock.

Nyxoah Company Profile (Get Rating)

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

See Also

Earnings History and Estimates for Nyxoah (NASDAQ:NYXH)

Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.